Murine CD8 T-cell functional avidity is stable in vivo but not in vitro: Independence from homologous prime/boost time interval and antigen density.
Animals
Antibody Formation
Antigen Presentation
Antigens
/ immunology
CD8-Positive T-Lymphocytes
/ immunology
Cells, Cultured
Immunization, Secondary
Mice
Mice, Inbred C57BL
Peptides
/ immunology
Protein Binding
Receptors, Antigen, T-Cell
/ metabolism
Vaccination
Vaccines, Subunit
/ immunology
Vaccines, Virus-Like Particle
/ immunology
Avidity regulation
Functional avidity
Prime/boost
T-cell receptor affinity
T-cell vaccination
Journal
European journal of immunology
ISSN: 1521-4141
Titre abrégé: Eur J Immunol
Pays: Germany
ID NLM: 1273201
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
15
08
2019
revised:
17
10
2019
accepted:
27
11
2019
pubmed:
1
12
2019
medline:
11
8
2020
entrez:
1
12
2019
Statut:
ppublish
Résumé
It is known that for achieving high affinity antibody responses, vaccines must be optimized for antigen dose/density, and the prime/boost interval should be at least 4 weeks. Similar knowledge is lacking for generating high avidity T-cell responses. The functional avidity (FA) of T cells, describing responsiveness to peptide, is associated with the quality of effector function and the protective capacity in vivo. Despite its importance, the FA is rarely determined in T-cell vaccination studies. We addressed the question whether different time intervals for short-term homologous vaccinations impact the FA of CD8 T-cell responses. Four-week instead of 2-week intervals between priming and boosting with potent subunit vaccines in C57BL/6 mice did not improve FA. Equally, similar FA was observed after vaccination with virus-like particles displaying low versus high antigen densities. Interestingly, FA was stable in vivo but not in vitro, depending on the antigen dose and the time interval since T-cell activation, as observed in murine monoclonal T cells. Our findings suggest dynamic in vivo modulation for equal FA. We conclude that low antigen density vaccines or a minimal 4-week prime/boost interval are not crucial for the T-cell's FA, in contrast to antibody responses.
Identifiants
pubmed: 31785153
doi: 10.1002/eji.201948355
pmc: PMC7187562
doi:
Substances chimiques
Antigens
0
Peptides
0
Receptors, Antigen, T-Cell
0
Vaccines, Subunit
0
Vaccines, Virus-Like Particle
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
505-514Subventions
Organisme : Swiss Cancer Research
ID : 3971-08-2016
Pays : International
Organisme : Swiss Cancer Research
ID : 4291-08-2017
Pays : International
Organisme : Ludwig Institute for Cancer Research
Pays : International
Organisme : NIBIB NIH HHS
ID : R01 EB022433
Pays : United States
Organisme : Alfred and Annemarie von Sick
Pays : International
Organisme : The Swiss National Science Foundation
ID : 310030-179459
Pays : International
Organisme : Cancer Research Institute
Pays : United States
Organisme : Université de Lausanne
Pays : International
Informations de copyright
© 2019 The Authors. European Journal of Immunology published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Références
Biochemistry. 1964 Jul;3:996-1008
pubmed: 14214095
J Immunol. 2004 Feb 1;172(3):1777-85
pubmed: 14734761
J Immunol. 2001 Oct 1;167(7):3818-28
pubmed: 11564799
J Immunol. 2007 Jul 15;179(2):748-51
pubmed: 17617563
J Immunol. 2014 Jan 1;192(1):200-5
pubmed: 24273000
J Immunol. 2005 May 15;174(10):5994-6004
pubmed: 15879092
J Immunol. 1999 Jan 15;162(2):989-94
pubmed: 9916724
Proc Natl Acad Sci U S A. 2014 Jan 28;111(4):1485-90
pubmed: 24474775
J Immunol. 2014 May 1;192(9):4061-8
pubmed: 24696232
J Clin Invest. 2013 Mar;123(3):1044-56
pubmed: 23391724
Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4102-7
pubmed: 8633023
Int Immunol. 2006 Mar;18(3):435-44
pubmed: 16431877
J Immunol. 2007 Sep 1;179(5):3203-13
pubmed: 17709536
J Virol. 1997 Aug;71(8):5764-8
pubmed: 9223463
Philos Trans R Soc Lond B Biol Sci. 2000 Mar 29;355(1395):357-60
pubmed: 10794054
Cancer Immunol Res. 2018 Sep;6(9):1025-1038
pubmed: 29915023
Sci Transl Med. 2012 Apr 4;4(128):128ra42
pubmed: 22491952
Eur J Immunol. 2007 Feb;37(2):406-15
pubmed: 17274003
Immunity. 1999 Apr;10(4):485-92
pubmed: 10229191
Int Immunol. 2002 Jan;14(1):31-7
pubmed: 11751749
Science. 2002 Nov 29;298(5599):1797-800
pubmed: 12459592
J Immunol. 2003 Feb 15;170(4):1822-9
pubmed: 12574347
J Exp Med. 1999 Feb 15;189(4):701-10
pubmed: 9989985
Nat Rev Immunol. 2004 Feb;4(2):123-32
pubmed: 15040585
PLoS One. 2013 Oct 25;8(10):e78686
pubmed: 24205294
JCI Insight. 2017 Jul 20;2(14):
pubmed: 28724801
Cancer Immunol Immunother. 2009 May;58(5):719-28
pubmed: 18836717
Clin Dev Immunol. 2012;2012:153863
pubmed: 23227083
Nature. 2014 Mar 27;507(7493):519-22
pubmed: 24531764
Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):15010-5
pubmed: 18809922
Eur J Immunol. 2006 Jul;36(7):1805-14
pubmed: 16761313
Sci Rep. 2017 Feb 03;7:41558
pubmed: 28155878
J Immunol. 2003 Sep 1;171(5):2251-61
pubmed: 12928369
Eur J Immunol. 2019 Oct;49(10):1457-1973
pubmed: 31633216
Cancer Immunol Immunother. 2013 Dec;62(12):1769-80
pubmed: 24114143
J Exp Med. 2007 Oct 29;204(11):2667-77
pubmed: 17954566
Annu Rev Immunol. 2007;25:171-92
pubmed: 17129182
J Exp Med. 2007 Oct 1;204(10):2473-85
pubmed: 17893201
Proc Natl Acad Sci U S A. 2008 Apr 1;105(13):5189-94
pubmed: 18362362
J Immunol. 2017 May 1;198(9):3494-3506
pubmed: 28348274
J Immunol. 2006 Jul 1;177(1):155-61
pubmed: 16785510
J Immunol. 2003 Mar 1;170(5):2599-604
pubmed: 12594287
PLoS Pathog. 2012 Sep;8(9):e1002889
pubmed: 23028307
J Virol. 2000 Apr;74(8):3486-93
pubmed: 10729122
Immunol Rev. 2009 May;229(1):27-40
pubmed: 19426213
Int Immunol. 2004 Nov;16(11):1549-59
pubmed: 15351787
Immunol Cell Biol. 2015 Oct;93(9):804-14
pubmed: 25804828
Immunity. 2000 Feb;12(2):161-70
pubmed: 10714682
J Immunol. 2003 Mar 1;170(5):2523-30
pubmed: 12594278
J Immunol. 1998 Jul 15;161(2):594-601
pubmed: 9670932
J Exp Med. 1998 May 18;187(10):1647-57
pubmed: 9584143
Cytometry A. 2016 Sep;89(9):816-25
pubmed: 27564267
Clin Cancer Res. 2017 Jul 1;23(13):3285-3296
pubmed: 27872103
Nat Immunol. 2001 Aug;2(8):711-7
pubmed: 11477407